|
US2019233845A1
|
|
Adenovectors for delivery of therapuetic genetic material into t cells
|
|
TW201629230A
|
|
Adenoviral vector encoding human atonal homolog-1 (hath1)
|
|
US2015297699A1
|
|
Malaria antigens and methods of use
|
|
US2015167018A1
|
|
Modified serotype 28 adenoviral vectors
|
|
US2015140025A1
|
|
Herpes simplex virus vaccine
|
|
EP2809346A1
|
|
Adenoviral vector-based malaria vaccine
|
|
BR112014008284A2
|
|
simian adenovirus (gorilla) or adenoviral vectors and methods of use
|
|
US2014248307A1
|
|
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
|
EP2764011A2
|
|
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
|
CA2850627A1
|
|
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
|
EP2654786A1
|
|
Adenoviral vector-based dengue fever vaccine
|
|
WO2012083297A2
|
|
Adenoviral vectors with modified hexon regions
|
|
WO2012021730A2
|
|
Respiratory syncytial virus (rsv) vaccine
|
|
MX2012005181A
|
|
Methods of propagating monkey adenoviral vectors.
|
|
CA2708367A1
|
|
Vaccine directed against adenovirus serotype 14
|
|
US2007232541A1
|
|
Methods of regulating angiogenisis through stabilization of pedf
|
|
US2008003236A1
|
|
Adenovirus fiber shaft composition and methods of use
|
|
BRPI0618441A2
|
|
Adenoviral vector
|
|
WO2007073513A2
|
|
Method for propagating adenoviral vectors encoding inhibitory gene products
|
|
AU2006284756A1
|
|
Adenoviral vector-based malaria vaccines
|
